The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 5, 2008, Pages 459-468

  Levi, Marcel ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Activated protein c; Antithrombin; Coagulation; Inflammation; Natural anticoagulants; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; COMPLEMENT COMPONENT C4B BINDING PROTEIN; CYTOKINE; DROTRECOGIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL PROTEIN C RECEPTOR; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROCOAGULANT; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTERY THROMBOSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FIBRIN DEPOSITION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; THROMBIN TIME; THROMBOGENESIS; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CRITICAL ILLNESS; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; INFLAMMATION; LIPOPROTEINS; PROTEIN C; PROTEIN-SERINE-THREONINE KINASES;

EID: 55049107958     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1092876     Document Type: Review

References (100)

1. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003;7:23-38
2. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257-1262
3. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-1259
4. van Deventer SJ, Buller HR, ten Cate JW, et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526
5. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-259
6. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006;32:5-10
7. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-120
8. Pixley RA, De LC, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61-68
9. Laterre PF, Wittebole X, Collienne C. Pharmacological inhibition of tissue factor. Semin Thromb Hemost 2006;32:71-76
10. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006;32:11-23
11. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S9-S14
12. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95:2387-2394
13. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996;81:1-41
14. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992;34(Suppl):S15-S27
15. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-2315
16. Osterud B, Rao LV, Olsen JO. Induction of tissue factor expression in whole blood - lack of evidence for the presence of tissue factor expression on granulocytes. Thromb Haemost 2000;83:861-867
17. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-935
18. Koyama T, Nishida K, Ohdama S, et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994;87:343-347
19. Gando S. Tissue factor in trauma and organ dysfunction. Semin Thromb Hemost 2006;32:48-53
20. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-2195
21. Franco RF, de Jonge E, Dekkers PE, et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 2000;96:554-559
22. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002;30:S294-S301
23. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;300:729-735
24. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698-2704
25. Levi M. Antithrombin in sepsis revisited. Crit Care 2005;9:624-625
26. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990; 144:383-390
27. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007;11(Suppl 5):S3
28. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86(1):51-56
29. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001;29:S90-S94
30. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348-1352
31. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000;83:639-643
32. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release of micro-particle-associated endothelial protein C receptor. Blood 2005;105:1515-1522
33. Mesters RM, Helterbrand J, Utterback BG, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000;28:2209-2216
34. Vary TC, Kimball SR. Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 1992;262:C445-C452
35. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 1991;372:1007-1013
36. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745
37. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-416
38. Garcia de Frutos P, Alim RI, Hardig Y, Zoller B, Dahlback B. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994;84:815-822
39. Taylor FBJ, Dahlback B, Chang AC, et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995;86:2642-2652
40. Taylor FBJ, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000;95:1680-1686
41. De Pont AC, Bakhtiari K, Hutten BA, et al. Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 2006;134:213-219
42. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activtion without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000;95:1124-1129
43. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2856
44. Mileno MD, Margolis NH, Clark BD, et al. Coagulation of whole blood stimulates interleukin-1 beta gene expression. J Infect Dis 1995;172:308-311
45. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:639-651
46. de Jonge E, Friederich PW, Levi M, van der Poll T. Activation of coagulation by administration of recombinant factor VIIa elcicits interleukin-6 and interleukin-8 release in healthy humen subjects. Clin Diagn Lab Immunol 2003;10:495-497
47. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264
48. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002;13:657-670
49. Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003;35:545-554
50. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93:157-164
51. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904
52. Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003;101:3029-3036
53. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998;89:233-241
54. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002;196:561-564
55. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001;184:258-274
56. Taylor FBJ, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925
57. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647
58. Hancock WW, Tsuchida A, Hau H, Thomson NM, Salem HH. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to biology and therapy. Transplant Proc 1992;24:2302-2303
59. Hancock WW, Grey ST, Hau L, et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 1995;60:1525-1532
60. White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000;110:130-134
61. Levi M, Dorffler-Melly J, Reitsma PH, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood 2003;101:4823-4827
62. Lay AJ, Donahue D, Tsai MJ, Castellino FJ. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007;109:1984-1991
63. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-1882
64. Ludeman MJ, Kataoka H, Srinivasan Y, et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 2005;280:13122-13128
65. Xu J, Qu D, Esmon NL, Esmon CT. Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem 2000;275:6038-6044
66. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000;165:4697-4703
67. Oganesyan V, Oganesyan N, Terzyan S, et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002;277:24851-24854
68. Feistritzer C, Sturn DH, Kaneider NC, Djanani A, Wiedermann CJ. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol 2003;112:375-381
69. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003;102:1499-1505
70. Hoffmann JN, Vollmar B, Laschke MW, et al. Micro-hemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004;32:1011-1017
71. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxininduced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878-3885
72. Shimizu S, Gabazza EC, Taguchi O, et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003;167:1416-1426
73. Zeng W, Matter WF, Yan SB, et al. Effect of drotrecogin alfa on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 2004;32:S302-S308
74. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005;105:3178-3184
75. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005;280:17286-17293
76. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:333-342
77. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003;373:65-70
78. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-3172
79. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000;157:1849-1862
80. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind study. Crit Care Med 2001;29:2081-2089
81. Zoldhelyi P, Chen ZQ, Shelat HS, McNatt JM, Willerson JT. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A 2001;98:4078-4083
82. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247
83. Levi M, ten Cate H, van der Poll T. Disseminated intravascular coagulation: state of the art. Thromb Haemost 1999;82:695-705
84. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878
85. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-97
86. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330
87. Taylor FBJ, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925
88. Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001;104:1171-1175
89. De Backer D, Verdant C, Chierego M, et al. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 2006;34:1918-1924
90. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation 1991;84:2454-2462
91. Gruber A, Marzec UM, Bush L, et al. Relative antithrombotic and antihemostatic effects of protein C activator versus low molecular weight heparin in primates. Blood 2007;109:3733-3740
92. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-2059
93. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
94. De Pont AC, Bakhtiari K, Hutten BA, et al. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. Crit Care 2005;9:R490-R497
95. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924-1933
96. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-19
97. Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007;176:483-490
98. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005;33:341-348
99. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005;171:1125-1128
100. Wang L, Bastarache JA, Wickersham N, et al. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007;36:497-503